Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral arterial intervention cases in New York: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 8% on average (237 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 112 | 12,515 | 46% |
| 2020 | 92 | 12,267 | 48% |
| 2021 | 97 | 13,686 | 51% |
| 2022 | 97 | 13,638 | 53% |
| 2023 | 95 | 13,668 | 55% |
| 2024 | 97 | 12,468 | 57% |
| 2025 from claims | – | 14,360 13,178–15,192 | 58% |
| 2026 forecast | – | 14,789 13,012–17,065 | 58% |
| 2027 forecast | – | 15,168 12,967–18,075 | 59% |
| 2028 forecast | – | 15,554 12,978–19,045 | 59% |
| 2029 forecast | – | 15,947 13,025–19,999 | 60% |
| 2030 forecast | – | 16,348 13,097–20,950 | 60% |
Iliac, femoropopliteal, and tibial angioplasty, stenting, atherectomy. Professional codes (what the surgeon bills): CPT 37220, 37221, 37224, 37225, 37226, 37227, 37228, 37229, 37230, 37231; the hospital bills MS-DRG 252, 253, 254.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 43% of the cases CMS names in New York; 38 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 24% inpatient hospital, 16% hospital outpatient, 4% surgery center, 56% office. The share outside the hospital has moved +12 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New Jersey | 55 | 8,709+2.3%/yr | +2.3%/yr | 8.0 | 77% | 12,700 in 2030+6.4%/yr |
| Pennsylvania | 34 | 4,796−11%/yr | −11%/yr | 3.3 | 15% | 4,870 in 2030+0.3%/yr |
| Massachusetts | 34 | 3,386−4.6%/yr | −4.6%/yr | 3.5 | 43% | 4,060 in 2030+3.1%/yr |
| Connecticut | 14 | 1,650−9%/yr | −9%/yr | 4.7 | 71% | 1,560 in 2030−1%/yr |
| New Hampshire | 5 | 534−11%/yr | −11%/yr | 2.3 | 0% | 1,240 in 2030+15%/yr |
| Rhode Island | 4 | 346−12%/yr | −12%/yr | 3.6 | 54% | 380 in 2030+1.5%/yr |
| Maine | 1 | 250−14%/yr | −14%/yr | 1.5 | 0% | 260 in 2030+0.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 109 | 13,452−13%/yr | −13%/yr | 7.71.7× | 80% | 12,500 in 2030−1.2%/yr |
| Superficial venous ablation | 132 | 8,630−5.2%/yr | −5.2%/yr | 4.51.6× | 97% | 9,880 in 2030+2.3%/yr |
| Thrombectomy, IVC filters & venous stents | 24 | 2,696−2.3%/yr | −2.3%/yr | 1.51.2× | 17% | 3,720 in 2030+5.5%/yr |
| Carotid revascularization | 32 | 1,508−6.4%/yr | −6.4%/yr | 0.80.7× | 0% | 1,510 in 20300%/yr |
| Aortic endografts (EVAR/TEVAR) | 7 | 818−5.7%/yr | −5.7%/yr | 0.51.1× | 0% | 860 in 2030+0.8%/yr |
Peripheral arterial intervention in every state, and its device makers · Every procedure market in New York · Every state · Compare with New Jersey
Medtronic leads with 56% of company spending on these surgeons in 2025, +14 pts on 2024.
In 2025, 11 companies reported engagement with New York’s surgeons worth $326K in consulting, speaking, meals and travel tied to these products, about $3,358 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 58 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
New York’s own discharge file counts every inpatient stay, whatever the payer: 12,145 peripheral angioplasty and stenting stays at 88 hospitals in 2024, against the Medicare-only figures above. The most commercial of the busy ones is GARNET HEALTH MEDICAL CENTER (39% commercial): where commercial rates leave the most room for a premium product.
| Hospital | Cases | Medicare | Commercial |
|---|---|---|---|
| MOUNT SINAI HOSPITAL NEW YORK | 1,647 | 80% | 10% |
| NYU LANGONE HOSPITALS NEW YORK | 682 | 65% | 18% |
| NEW YORK-PRESBYTERIAN HOSPITAL NEW YORK | 556 | 54% | 24% |
| MONTEFIORE MEDICAL CENTER BRONX | 529 | 60% | — |
| KALEIDA HEALTH BUFFALO | 470 | 62% | 21% |
| MOUNT SINAI WEST NEW YORK | 468 | 82% | 13% |
| NEW YORK-PRESBYTERIAN/BROOKLYN METHO BROOKLYN | 359 | 69% | — |
| STRONG MEMORIAL HOSPITAL ROCHESTER | 352 | 59% | 20% |
New York only: MedaRep has no other state’s all-payer file yet. Counted by principal procedure (Peripheral angioplasty and stenting: every artery but the coronaries and carotids, veins included.). Medicare here includes Medicare Advantage. A hospital with 10 or fewer such stays, or a payer share of 10 or fewer, is not shown. Source: New York State Department of Health, SPARCS de-identified inpatient discharges (health.data.ny.gov). The New York State Department of Health makes no representation, warranty or guarantee relating to the data or analyses derived from these data. Accessed 2026-11-11.